MK-8722 is a potent, direct, allosteric activator of all 12 mammalian pan-AMPK complexes.
research use only
Cat.No.E1031
| Related Targets | PI3K Akt mTOR GSK-3 ATM/ATR DNA-PK PDPK1 PTEN PP2A PDK |
|---|---|
| Other AMPK Inhibitors | Dorsomorphin Dihydrochloride Dorsomorphin (Compound C) AICAR (Acadesine) A-769662 GSK621 WZ4003 ex229 (compound 991) Phenformin HCl HTH-01-015 BAY-3827 |
|
In vitro |
DMSO
: 90 mg/mL
(200.04 mM)
Ethanol : 2 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 449.89 | Formula | C24H20ClN3O4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1394371-71-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | OC1COC2C(COC12)OC3=NC4=NC(=C(Cl)C=C4[NH]3)C5=CC=C(C=C5)C6=CC=CC=C6 | ||
| Targets/IC50/Ki |
pan-AMPK
|
|---|---|
| In vitro |
MK-8722 activates pAMPK complexes with increased potency and magnitude versus AMP. In primary mouse hepatocytes, HepG2 cells, or primary human myocytes, this compound results in the phosphorylation of a number of additional known targets of pAMPK, and the most potent off-target activity observed for it is against the serotonin 5-HT2A receptor. |
| In vivo |
Pharmacological pan-AMPK activation by MK-8722 leads to chronically sustainable improvements in glucose homeostasis, including the amelioration of insulin resistance and hyperglycemia. Acute treatment with this compound (30 mpk) significantly suppress blood glucose and insulin levels. In mice, chronic administration of this chemical also increases muscle Glut4 protein levels. In rhesus monkeys, it results in cardiac hypertrophy associated with increased cardiac and skeletal muscle glycogen. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.